These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31431785)

  • 1. Intranasal Glucagon.
    Kalra S; Dhingra M
    J Pak Med Assoc; 2019 Aug; 69(8):1219-1221. PubMed ID: 31431785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
    Pontiroli AE; Ceriani V
    Diabetes Obes Metab; 2018 Aug; 20(8):1812-1816. PubMed ID: 29652110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal Glucagon: A New Way to Treat Hypoglycemic Emergencies.
    Lowe RN; Trujillo JM
    Ann Pharmacother; 2020 Aug; 54(8):780-787. PubMed ID: 32052651
    [No Abstract]   [Full Text] [Related]  

  • 4. The New Wave.
    Neithercott T
    Diabetes Forecast; 2016; 69(2):42-5. PubMed ID: 27048047
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and Usability of Intranasal Glucagon for the Management of Hypoglycemia in Patients With Diabetes: A Systematic Review.
    Singh-Franco D; Moreau C; Levin AD; Rosa D; Johnson M
    Clin Ther; 2020 Sep; 42(9):e177-e208. PubMed ID: 32873417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful administration of intranasal glucagon in the out-of-hospital environment.
    Sibley T; Jacobsen R; Salomone J
    Prehosp Emerg Care; 2013; 17(1):98-102. PubMed ID: 22971130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
    La Sala L; Pontiroli AE
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.
    Deeb LC; Dulude H; Guzman CB; Zhang S; Reiner BJ; Piché CA; Pradhan S; Zhang XM
    Pediatr Diabetes; 2018 Aug; 19(5):1007-1013. PubMed ID: 29512902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.
    Stenninger E; Aman J
    Diabetologia; 1993 Oct; 36(10):931-5. PubMed ID: 8243872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.
    Seaquist ER; Dulude H; Zhang XM; Rabasa-Lhoret R; Tsoukas GM; Conway JR; Weisnagel SJ; Gerety G; Woo VC; Zhang S; Carballo D; Pradhan S; Piché CA; Guzman CB
    Diabetes Obes Metab; 2018 May; 20(5):1316-1320. PubMed ID: 29504662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.
    Pontiroli AE
    J Diabetes Sci Technol; 2015 Jan; 9(1):38-43. PubMed ID: 25385946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.
    Haymond MW; DuBose SN; Rickels MR; Wolpert H; Shah VN; Sherr JL; Weinstock RS; Agarwal S; Verdejo AS; Cummins MJ; Newswanger B; Beck RW;
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2994-3001. PubMed ID: 28591776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Needle-free nasal delivery of glucagon for treatment of diabetes-related severe hypoglycemia: toxicology of polypropylene resin used in delivery device.
    Reno FE; Edwards CN; Bendix Jensen M; Török-Bathó M; Esdaile DJ; Piché C; Triest M; Carballo D
    Cutan Ocul Toxicol; 2016 Sep; 35(3):242-7. PubMed ID: 26426957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.
    Hawkes CP; De Leon DD; Rickels MR
    Curr Diab Rep; 2019 Sep; 19(10):97. PubMed ID: 31493043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon.
    Slama G; Alamowitch C; Desplanque N; Letanoux M; Zirinis P
    Diabetologia; 1990 Nov; 33(11):671-4. PubMed ID: 2076798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Think Fast.
    Tucker ME
    Diabetes Forecast; 2016; 69(2):88-9. PubMed ID: 27048054
    [No Abstract]   [Full Text] [Related]  

  • 18. Octreotide as antidote for sulfonylurea-induced hypoglycemia.
    Schier JG; Hirsch ON; Chu J
    Ann Emerg Med; 2001 Apr; 37(4):417-8. PubMed ID: 11275841
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravenous glucagon in a deliberate insulin overdose in an adolescent with type 1 diabetes mellitus.
    White M; Zacharin MR; Werther GA; Cameron FJ
    Pediatr Diabetes; 2016 Feb; 17(1):66-9. PubMed ID: 25229989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
    Rickels MR; Ruedy KJ; Foster NC; Piché CA; Dulude H; Sherr JL; Tamborlane WV; Bethin KE; DiMeglio LA; Wadwa RP; Ahmann AJ; Haller MJ; Nathan BM; Marcovina SM; Rampakakis E; Meng L; Beck RW;
    Diabetes Care; 2016 Feb; 39(2):264-70. PubMed ID: 26681725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.